{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T04:11:51Z","timestamp":1747368711117,"version":"3.40.5"},"reference-count":11,"publisher":"American Academy of Insurance Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Insur Med"],"published-print":{"date-parts":[[2023]]},"abstract":"<jats:p>\n          <jats:bold>Objective.\u2014<\/jats:bold>Determine the seroprevalence of SARS-CoV-2 infection and vaccination in a population applying for life insurance.<\/jats:p>\n        <jats:p>\n          <jats:bold>Setting.\u2014<\/jats:bold>This is a cross-sectional study of 2584 US life insurance applicants, to determine the seroprevalence of antibodies to COVID-19. This convenience sample was selected on two consecutive days April 25-26, 2022.<\/jats:p>\n        <jats:p>\n          <jats:bold>Results.\u2014<\/jats:bold>For COVID-19, 97.3% are seropositive, and 63.9% have antibodies to nucleocapsid protein, a marker of prior infection. An additional, 33.7% have been vaccinated with no serologic evidence of infection.<\/jats:p>\n        <jats:p>\n          <jats:bold>Methodology.\u2014<\/jats:bold>Serum and urine samples from a nationwide group of insurance applicants for routine risk assessment were collected. The examination of applicants typically occurs, in their homes, their place of employment, or a clinic. The paramedic exam occurs 7-14 days after the insurance application. Before the exam, an office assistant calls the applicant and inquires if they have been in contact with a person with SARS-CoV-2, been ill within the last 2 weeks, felt sick, or recently had a fever. If the applicant answers yes, the exam is rescheduled.<\/jats:p>\n        <jats:p>Before sample collection, the applicant reads and signs a consent form to release medical information and testing. Next, the examiner records the applicant\u2019s blood pressure, height, and weight. Then, a blood and a urine sample are collected and sent with the consent form to our laboratory via Federal Express.<\/jats:p>\n        <jats:p>On April 25-26, 2022, we tested 2584 convenience samples from adult insurance applicants for the presence of antibodies to nucleocapsid and spike proteins from SARS-CoV-2. As a standard practice, we reported the client-specified test profile results to our life insurance carriers. In contrast, the COVID-19 test results were only available to the authors.<\/jats:p>\n        <jats:p>\n          <jats:bold>Patient and Public Involvement.\u2014<\/jats:bold>There was no patient involvement in study design, reporting of results, or journal publication selection. There was patient consent to publish de-identified study results. No public involvement occurred in the creation or completion of the study. The authors thank the participants in this study for approving the use of their blood samples to further society\u2019s understanding of the SARS-CoV-19 pandemic.<\/jats:p>\n        <jats:p>\n          <jats:bold>Ethics Review.\u2014<\/jats:bold>Western Institutional Review Board reviewed the study design and determined it to be exempt under the Common Rule and applicable guidance. Therefore, it is exempt under 45 CFR \u00a7 46.104(d)(4) from using de-identified study samples for epidemiologic investigation, WIRB Work Order #1-1324846-1. In addition, all test subjects had signed a consent allowing research of their blood and urine samples with the removal of personally identifiable information.<\/jats:p>\n        <jats:p>\n          <jats:bold>Results.\u2014<\/jats:bold>The combined seroprevalence for antibodies to nucleocapsid, a marker of prior infection, and antibodies to spike protein, an indicator of either previous infection or vaccination, was 97.3%. Higher infection rates occur in younger vs older age groups, with a non-statistical difference for vaccinated and acquired natural immunity. For the age group 16-84, the total estimated seroprevalence of COVID-19 in the US is 249 million cases.<\/jats:p>\n        <jats:p>\n          <jats:bold>Conclusions.<\/jats:bold>\u2014The US population has widespread immune resistance to current variants of COVID-19 due to prior infection or vaccination. The infectivity of new variants and silent disease, independent of previous infection or vaccination, are the driving force behind the sporadic increase in clinical SARS-CoV-2 cases.<\/jats:p>","DOI":"10.17849\/insm-50-1-49-53.1","type":"journal-article","created":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T16:06:43Z","timestamp":1695139603000},"page":"49-53","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence of Antibodies to COVID-19 Due to Infection or Vaccination in US Adults"],"prefix":"10.17849","volume":"50","author":[{"given":"Robert L","family":"Stout","sequence":"first","affiliation":[{"name":"Stout \u2013 Chief Science Officer, Clinical Reference Laboratory, Inc."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven J","family":"Rigatti","sequence":"additional","affiliation":[{"name":"Rigatti \u2013 Rigatti Risk Analytics."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7324","reference":[{"article-title":"COVID Data Tracker","year":"2022","key":"i0743-6661-50-1-49-ref1","unstructured":"Centers for Disease Control and Prevention.\nCOVID Data Tracker.\nAtlanta, GA:\nUS Department of Health and Human Services, CDC;\n2022,\nJuly10.\nhttps:\/\/covid.cdc.gov\/covid-data-tracker"},{"article-title":"Centers for Disease Control and Prevention","year":"2020","key":"i0743-6661-50-1-49-ref2","unstructured":"Coronavirus (COVID-19): symptoms of corona-virus.\nCenters for Disease Control and Prevention.\n2020.\nDecember 7, 2020,\nhttps:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/symptoms-testing\/symptoms.html"},{"key":"i0743-6661-50-1-49-ref3","series-title":"N Engl J Med","first-page":"1207","article-title":"This article was published on February 16, 2022, and updated on March 31, 2022 at NEJM.org","volume":"386","author":"Hall","year":"2022","unstructured":"Hall\n              V,\n            \n            \n              Foulkes\n              S,\n            \n            \n              Insalata\n              F,\n            \n          \n          et al.\n          for the SIREN Study Group Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection.\nThis article was published on February 16, 2022, and updated on March 31, 2022 at NEJM.org.\nN Engl J Med.\n2022;\n386:\n1207-\n1220. DOI:\nhttp:\/\/dx.doi.org\/10.1056\/NEJMoa2118691"},{"key":"i0743-6661-50-1-49-ref4","series-title":"N Engl J Med","first-page":"21","article-title":"Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections","volume":"387","author":"Altarawneh","year":"2022","unstructured":"Altarawneh\n              HN,\n            \n            \n              Chemaitelly\n              H,\n            \n            \n              Ayoub\n              HH,\n            \n          \n          et al.\n          Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections.\nN Engl J Med.\n2022;\n387:\n21-\n34."},{"article-title":"R: A language and environment for statistical computing","year":"2019","key":"i0743-6661-50-1-49-ref5","unstructured":"R Core Team (\n2019).\nR: A language and environment for statistical computing.\nR Foundation for Statistical Computing,\nVienna, Austria. URL\nhttps:\/\/www.R-project.org\/."},{"article-title":"RStudio: Integrated Development for R. RStudio","year":"2020","key":"i0743-6661-50-1-49-ref6","unstructured":"R-Studio Team (\n2020).\nRStudio: Integrated Development for R. RStudio,\nPBC,\nBoston, MA URL\nhttp:\/\/www.rstudio.com\/."},{"key":"i0743-6661-50-1-49-ref7","unstructured":"Aug 1, 2022 \u2014 The 2020 Census counted every person living in the United States and the five US territories.\nhttps:\/\/www.census.gov> 2020census;\nhttps:\/\/www.census.gov\/quickfacts\/fact\/table\/US\/AGE295221","article-title":"Aug 1, 2022 \u2014 The 2020 Census counted every person living in the United States and the five US territories"},{"key":"i0743-6661-50-1-49-ref8","series-title":"Sci Rep","first-page":"2628","article-title":"mRNA vaccine-induced antibodies more effective than natural immunity in neutralizing SARS-CoV-2 and its high affinity variants","volume":"12","author":"Yu","year":"2022","unstructured":"Yu\n              Y,\n            \n            \n              Esposito\n              D,\n            \n            \n              Zhigang Kang,\n              Z,\n            \n          \n          et al.\n          mRNA vaccine-induced antibodies more effective than natural immunity in neutralizing SARS-CoV-2 and its high affinity variants.\nSci Rep.\n2022;\n12:\n2628.\nhttps:\/\/doi.org\/10.1038\/s41598-022-06629-2"},{"key":"i0743-6661-50-1-49-ref9","unstructured":"CDC reports aggregate counts of COVID-19 cases and death numbers daily online.\nData on the COVID-19 website and CDC\u2019s COVID Data Tracker,\nhttps:\/\/data.cdc.gov\/Case-Surveillance\/United-States-COVID-19-Cases-and-Deaths-by-State-o\/9mfq-cb36\/data","article-title":"CDC reports aggregate counts of COVID-19 cases and death numbers daily online"},{"key":"i0743-6661-50-1-49-ref10","series-title":"Open JAMA Network","doi-asserted-by":"publisher","first-page":"e211552","DOI":"10.1001\/jamanetworkopen.2021.15522021;4(3):e211552","article-title":"Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020","volume":"4","author":"Stout","year":"2021","unstructured":"Stout\n              RL,\n            \n            \n              Rigatti\n              SJ.\n            \n          \n          Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020.\nOpen JAMA Network.\n2021;\n4:\ne211552. doi:\n10.1001\/jamanetworkopen.2021.15522021;4(3):e211552."},{"key":"i0743-6661-50-1-49-ref11","series-title":"MMWR Morb Mortal Wkly Rep","first-page":"606","article-title":"Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies \u2014 United States, September 2021\u2013February 2022","volume":"71","author":"Clarke","year":"2022","unstructured":"Clarke\n              KE,\n            \n            \n              Jones\n              JM,\n            \n            \n              Deng\n              Y,\n            \n          \n          et al.\n          Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies \u2014 United States, September 2021\u2013February 2022.\nMMWR Morb Mortal Wkly Rep.\n2022;\n71:\n606-\n608. DOI:\nhttp:\/\/dx.doi.org\/10.15585\/mmwr.mm7117e3external icon"}],"container-title":["Journal of Insurance Medicine"],"original-title":[],"link":[{"URL":"https:\/\/jim.kglmeridian.com\/view\/journals\/insm\/50\/1\/article-p49.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/meridian.allenpress.com\/jim\/article-pdf\/50\/1\/49\/3263255\/i0743-6661-50-1-49.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jim.kglmeridian.com\/downloadpdf\/journals\/insm\/50\/1\/article-p49.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jim.kglmeridian.com\/downloadpdf\/journals\/insm\/50\/1\/article-p49.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:39:25Z","timestamp":1747355965000},"score":1,"resource":{"primary":{"URL":"https:\/\/jim.kglmeridian.com\/view\/journals\/insm\/50\/1\/article-p49.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":11,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.17849\/insm-50-1-49-53.1","relation":{},"ISSN":["0743-6661"],"issn-type":[{"type":"print","value":"0743-6661"}],"subject":[],"published":{"date-parts":[[2023]]}}}